Melatonin Supplementation: Sleep Science

Why Your Melatonin Pill Isn’t Helping—And What Actually Works

Exogenous melatonin reduces sleep onset latency by ~7 minutes on average—but its primary clinical value lies in resetting circadian timing, not treating general insomnia. For circadian rhythm disorders like delayed-sleep-phase-disorder, low-dose (0.3–1 mg) melatonin taken at precisely timed intervals is significantly more effective than higher doses or inconsistent timing.

How Melatonin Supplementation Really Works

Exogenous melatonin reduces sleep latency by 7 minutes on average

Meta-analyses of randomized controlled trials—including a landmark 2013 Cochrane review and a 2021 JAMA Internal Medicine analysis—consistently report that oral melatonin shortens objective sleep onset latency by approximately 7 minutes compared to placebo. This effect holds across diverse adult populations but diminishes sharply in older adults (>65 years), likely due to age-related reductions in melatonin receptor density (MT1/MT2) in the suprachiasmatic nucleus (SCN). Importantly, this modest latency reduction does not translate into meaningful improvements in total sleep time or sleep efficiency for most individuals with chronic insomnia. The 7-minute benefit reflects melatonin’s role as a *chronobiotic*—a timing signal—not a sedative. Unlike benzodiazepines or orexin antagonists, melatonin does not increase GABAergic inhibition or suppress cortical arousal; instead, it lowers core body temperature and dampens SCN-driven wake-promoting signals via MT1-mediated inhibition of neuronal firing.

Most effective for circadian rhythm disorders—not general insomnia

Clinical guidelines from the American Academy of Sleep Medicine (AASM) and the European Sleep Research Society classify melatonin as “recommended” for circadian rhythm disorders—including circadian-rhythm-disorders such as jet lag, shift work disorder, and non-24-hour sleep–wake disorder—but “not recommended” for chronic insomnia disorder. This distinction arises from mechanistic differences: insomnia involves hyperarousal, dysfunctional sleep conditioning, and limbic–prefrontal dysregulation, while circadian misalignment stems from desynchrony between endogenous pacemaker output and environmental time cues. In delayed sleep phase disorder (DSPD), for example, melatonin advances the dim light melatonin onset (DLMO)—the biological marker of circadian phase—by up to 1.5 hours when administered 5–7 hours before habitual bedtime. A 2022 RCT in *Sleep* demonstrated that 0.5 mg melatonin given at DLMO-6h restored alignment with societal schedules in 68% of DSPD patients after four weeks, whereas cognitive behavioral therapy for insomnia (CBT-I) showed no phase-shifting capacity.

Low dose (0.3–1 mg) often as effective as higher doses

Pharmacokinetic studies reveal that oral melatonin exhibits saturable absorption and rapid hepatic metabolism (via CYP1A2), resulting in nonlinear dose–response curves. Doses above 1 mg produce supraphysiological plasma concentrations (>1000 pg/mL) that overwhelm MT1/MT2 receptor affinity and trigger off-target binding—potentially activating quinone reductase or calmodulin pathways linked to next-day grogginess. In contrast, 0.3 mg achieves peak serum levels (~60–90 pg/mL) closely mirroring endogenous nocturnal peaks (40–120 pg/mL) and sustains receptor occupancy long enough to entrain the SCN. A double-blind crossover trial published in *Journal of Clinical Sleep Medicine* found identical phase-advancing effects and subjective sleep quality between 0.3 mg and 3 mg groups in DSPD patients—yet the high-dose group reported significantly more morning fatigue and headache. This supports the principle that *physiological mimicry*, not pharmacological potency, drives efficacy.

Timing more important than dose for circadian effects

Melatonin’s chronobiotic action follows a phase-response curve (PRC): administration in the late afternoon/early evening causes phase advances; administration in the early morning causes phase delays; administration at night (during endogenous secretion) has minimal shifting effect. The magnitude and direction of phase shift depend almost entirely on *when* melatonin is ingested relative to DLMO—not how much is taken. For instance, taking 0.5 mg at 8 p.m. may advance DLMO by 90 minutes in a person whose natural DLMO is at 11 p.m., but the same dose at midnight yields negligible shift. Wearable-based DLMO estimation (using salivary melatonin assays or wrist actigraphy-derived temperature nadirs) enables personalized timing—yet most consumers take melatonin haphazardly, often at bedtime, missing the therapeutic window entirely.

Practical Applications: How to Use Melatonin Correctly

Determine your DLMO: Collect saliva samples every 30 minutes from 8 p.m. to midnight; DLMO is defined as the time when melatonin exceeds 4 pg/mL on two consecutive samples. Alternatively, use validated algorithms based on sleep logs and midpoint of sleep.
Administer 0.3–1 mg orally 5–7 hours before DLMO: For DSPD with DLMO at 1:00 a.m., take melatonin between 8:00–10:00 p.m. Maintain this timing daily for ≥14 days to consolidate phase shifts.
Pair with timed bright light exposure: After advancing sleep onset, expose to ≥3000 lux light upon waking (e.g., 7 a.m.) for 30 minutes to reinforce the new phase. Avoid blue light after 7 p.m.

Comparing Melatonin Strategies

Approach	Primary Mechanism	Best For	Risk of Next-Day Impairment
0.3 mg at DLMO−6h	MT1/MT2 receptor agonism in SCN	Delayed-sleep-phase-disorder	Very low
3 mg at bedtime	Nonselective receptor saturation + off-target effects	Transient sleep onset difficulty (short-term)	Moderate to high
Extended-release 2 mg	Sustained plasma elevation beyond physiological range	Older adults with low endogenous production	High (especially in CYP1A2 slow metabolizers)
Light therapy alone	Retinohypothalamic tract activation → SCN phase shift	Phase delay or advance without pharmacologic intervention	Negligible

Common Mistakes and Misconceptions

Taking melatonin at bedtime instead of 5–7 hours before DLMO: This misses the phase-shifting window and only provides weak soporific effect.
Assuming higher doses improve efficacy: Doses >1 mg saturate receptors, increase metabolite load, and elevate risk of residual sedation without added chronobiological benefit.
Using melatonin daily for chronic insomnia: Long-term use shows no sustained improvement in sleep architecture or daytime functioning and may blunt endogenous secretion.

Expert Insight

“Melatonin is not a sleeping pill—it’s a timing pill. Its power lies in precision: the right dose at the right phase. Prescribing 5 mg ‘for insomnia’ is like setting a clock by throwing darts at the face.” — Dr. Thomas Wehr, former Chief of the Clinical Psychobiology Branch at the National Institute of Mental Health, pioneer in human circadian physiology

FAQ

What is the best melatonin dose for sleep?

For circadian alignment, 0.3–1 mg is optimal. For short-term sleep onset support, 0.5–1 mg 30–60 minutes before bed may reduce latency—but this does not treat underlying insomnia pathology.

Is melatonin safe for long-term use?

Short-term use (<3 months) is well tolerated. Long-term safety data are limited; some studies suggest possible blunting of endogenous production with nightly dosing above 0.3 mg.

Does melatonin help with jet lag?

Yes—when timed correctly. Take 0.5 mg daily starting 2 days before travel, adjusted to destination bedtime: for eastward travel, take it in the early evening local time; for westward, take it at bedtime local time.

Can I take melatonin with other sleep medications?

Concomitant use with benzodiazepines or sedating antidepressants increases risk of excessive CNS depression. Avoid combining unless under direct supervision by a sleep specialist.